- Home
- WIA vs CHRS Comparison
WIA vs CHRS Comparison
Compare WIA & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WIA
- CHRS
- Stock Information
- Founded
- WIA 2003
- CHRS 2010
- Country
- WIA United States
- CHRS United States
- Employees
- WIA N/A
- CHRS N/A
- Industry
- WIA Trusts Except Educational Religious and Charitable
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WIA Finance
- CHRS Health Care
- Exchange
- WIA Nasdaq
- CHRS Nasdaq
- Market Cap
- WIA 192.9M
- CHRS 84.2M
- IPO Year
- WIA N/A
- CHRS 2014
- Fundamental
- Price
- WIA $8.40
- CHRS $0.73
- Analyst Decision
- WIA
- CHRS Buy
- Analyst Count
- WIA 0
- CHRS 3
- Target Price
- WIA N/A
- CHRS $4.68
- AVG Volume (30 Days)
- WIA 39.2K
- CHRS 1.3M
- Earning Date
- WIA 01-01-0001
- CHRS 08-07-2025
- Dividend Yield
- WIA 12.29%
- CHRS N/A
- EPS Growth
- WIA N/A
- CHRS N/A
- EPS
- WIA N/A
- CHRS N/A
- Revenue
- WIA N/A
- CHRS $272,251,000.00
- Revenue This Year
- WIA N/A
- CHRS N/A
- Revenue Next Year
- WIA N/A
- CHRS $106.56
- P/E Ratio
- WIA N/A
- CHRS N/A
- Revenue Growth
- WIA N/A
- CHRS 19.87
- 52 Week Low
- WIA $7.56
- CHRS $0.66
- 52 Week High
- WIA $8.91
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- WIA 69.19
- CHRS 41.45
- Support Level
- WIA $8.25
- CHRS $0.72
- Resistance Level
- WIA $8.42
- CHRS $0.77
- Average True Range (ATR)
- WIA 0.07
- CHRS 0.04
- MACD
- WIA 0.02
- CHRS 0.00
- Stochastic Oscillator
- WIA 93.33
- CHRS 13.65
About WIA Western Asset Inflation-Linked Income Fund
Western Asset Inflation Linked Income Fund is a diversified, closed-end management investment company. The primary investment objective of the group is to provide current income while its secondary investment objective is capital appreciation. Under normal market conditions and at the time of purchase, the Fund will invest at least 80% of its total managed assets in inflation-linked securities and at least 60% of its total managed assets in U.S. Treasury Inflation Protected Securities (TIPS). The Fund may also invest up to 40% of its total managed assets in non-U.S. dollar investments.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.